Immuneering (NASDAQ:IMRX - Get Free Report)'s stock had its "buy" rating restated by Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $13.00 price objective on the stock.
Several other analysts have also issued reports on the company. Morgan Stanley lowered Immuneering from an "equal weight" rating to an "underweight" rating in a research note on Friday, December 13th. Needham & Company LLC restated a "buy" rating and issued a $15.00 price target on shares of Immuneering in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $12.80.
Check Out Our Latest Analysis on IMRX
Immuneering Price Performance
Shares of NASDAQ IMRX traded down $0.36 during midday trading on Wednesday, reaching $2.00. 4,851,376 shares of the stock were exchanged, compared to its average volume of 17,431,006. The business has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $1.77. The company has a market capitalization of $62.10 million, a price-to-earnings ratio of -1.02 and a beta of -0.34. Immuneering has a 12 month low of $1.00 and a 12 month high of $7.68.
Institutional Trading of Immuneering
Hedge funds have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. acquired a new stake in shares of Immuneering during the third quarter worth $25,000. Corsair Capital Management L.P. acquired a new stake in Immuneering in the 3rd quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering in the 2nd quarter worth about $44,000. XTX Topco Ltd boosted its holdings in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock valued at $44,000 after purchasing an additional 9,274 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in shares of Immuneering during the 2nd quarter worth approximately $67,000. 67.65% of the stock is owned by institutional investors and hedge funds.
Immuneering Company Profile
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
